Amgen (AMGN) has had a strong performance in the bio-tech market. The company has reported robust fourth quarter and full year 2025 financial results. Analysts from various organizations including RBC, Guggenheim, and UBS have raised their price targets for Amgen, following its Q4 outcomes and considering its vital drug momentum. The stock for Amgen has reached 52-week highs, indicating an encouraging buy signal. Apart from the revenue growth, Amgen's stock has proven beneficial to long-term investors. According to the released Q4 transcript, Amgen prophesies a positive 2026 outlook, with a primary focus on obesity. It reported beating Street estimates and pointed out that patients need more weight-loss options. The company's revenue soared due to a double-digit volume boost. Furthermore, Amgen has seen a product portfolio expansion and pipeline progress, which is driving its outlook. In addition, the organisation is reshaping its Immunology Focus and broader R&D narrative. Amgen expects strong price appreciation in the future. However, the company has been faced with some challenges, including a lawsuit related to 340B, and regulatory tensions on Tavneos. It has also ended the collaboration with Kyowa Kirin Rocatinlimab.
Amgen AMGN News Analytics from Tue, 02 Sep 2025 07:00:00 GMT to Sat, 07 Feb 2026 08:59:45 GMT -
Rating 9
- Innovation 8
- Information 9
- Rumor 7
